Investment
Features
FeesSafety
Academy
More
Pluang+

US-China summit tests US influence amid allies' shifting loyalties and China's growing leverage.

Market News
23 Sep 2026
CNBC
View Source
Neutral
US-China summit tests US influence amid allies' shifting loyalties and China's growing leverage.

President Donald Trump meets Chinese President Xi Jinping amid a complex global landscape where US allies are less willing to align fully with Washington against China. Despite the US maintaining advantages through its alliances and technology control, confidence in the US as a reliable partner has dropped sharply in key allied countries like Canada and Germany. China has strengthened its global trade ties and leveraged critical resources like rare earth elements to counter US pressure, complicating efforts to isolate Beijing. The summit will focus on economic and diplomatic leverage points including Taiwan, trade, and Iran, testing whether the US can maintain a united front or if China’s growing influence will reshape global alliances.

The Trump-Xi meeting amid shifting global alliances is contextualized here with Basic Materials sector data from Pluang as of Sep 23, 2026 21:22 WIB. Among 38 US stocks, 10 rose and 28 fell. Notably, AEM traded at USD 193.80 with a 1-day change of -4.79% and a typical hold time of 55 days, while KGC was priced at USD 27.36, down 4.67%, held typically for 52 days. SLI, at USD 2.12, fell 4.30% with a shorter hold time of 21 days, and both KGC and SLI saw 100% buy order activity on Pluang.

More News

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
1 hour ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
1 hour ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
2 hours ago
Oppenheimer cuts Nike price target to $52 amid sales drop and economic challenges, but sees 45% upside potential.

Oppenheimer cuts Nike price target to $52 amid sales drop and economic challenges, but sees 45% upside potential.

Oppenheimer lowered Nike's price target to $52 from a higher level, reflecting concerns over falling sales and macroeconomic challenges. Despite Nike's stock trading near its 52-week low around $35.35, the new target implies a potential 44.85% upside...

Analyst Insights
Bearish
2 hours ago
Stifel upgrades Microsoft to Buy, citing strong Azure and Copilot growth potential.

Stifel upgrades Microsoft to Buy, citing strong Azure and Copilot growth potential.

Stifel Financial upgraded Microsoft from Hold to Buy, raising its price target to $575 due to strong growth prospects in Azure cloud services and Microsoft 365 Copilot. The analyst highlighted Azure's 43% year-over-year revenue growth and over 30 mil...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App